2022/05/30 by Michael R. McClung, Micol S. Rothman, E. Michael Lewiecki +4 · 1 citation
Medicine · #Bone health and osteoporosis research #Bone health and treatments #Hip and Femur Fractures
paper · pdf · doi:10.1080/00325481.2022.2069582
openalex publication_date 2022/05/30 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more effectively than oral bisphosphonates, providing strong justification for the use of these agents as the initial therapy or after anti-remodeling agents in patients at very high risk of fracture. At the end of a 12-to-24-month course of osteoanabolic therapy, transitioning to a potent anti-remodeling agent maintains and enhances the treatment benefit. This review describes the clinical applications of osteoanabolic therapy for osteoporosis.